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Abstract
Objectives—We aimed to prepare dried-blood-spot (DBS) quality control (QC) materials for 
galactose-1-phosphate uridyltransferase (GALT), to evaluate their stability during storage and use, 
and to evaluate their performance in five DBS GALT test methods.
Design and Methods—We prepared and characterized GALT-normal and GALT-deficient 
DBS materials and compared GALT activities in DBSs after predetermined storage intervals at 
controlled temperatures and humidities. External evaluators documented the suitability of the DBS 
QC materials for use in five GALT test methods.
Results—GALT activity losses from DBSs stored in low (<30%) humidity for 14 days at 45°C, 
35 days at 37°C, 91 days at room temperature, 182 days at 4°C, and 367 days at −20°C were 54%, 
53%, 52% 23%, and 7% respectively. In paired DBSs stored in high humidity (>50%) for identical 
intervals, losses were: 45°C—68%; 37°C—79%; room temperature—72%, and 4°C—63%. 
GALT activities in DBSs stored at 4°C were stable throughout 19 excursions to room temperature. 
Twenty-five of 26 external evaluators, using five different GALT test methods, classified the 
GALT-deficient DBSs as “outside normal limits”. All evaluators classified the GALT-normal 
DBSs as “within normal limits”.
Conclusions—Most of the GALT activity loss from DBSs stored at elevated or room 
temperature was attributable to the effects of storage temperature. Most of the loss from DBSs 
stored at 4°C was attributable to the effects of elevated humidity. Loss from DBSs stored at −20°C 
was insignificant. The DBS materials were suitable for monitoring performance of all five GALT 
test methods.
INTRODUCTION
Galactosemia is a rare inborn metabolic condition with a calculated incidence of 1:53,261 in 
the United States (US) [1]. Galactose is formed by enzymatic hydrolysis of lactose (milk 
sugar) and is converted to glucose by a series of enzymatic reactions. Although a deficiency 
in any one of three enzymes involved in the conversion of galactose to glucose― 
galactokinase, galactose-1- phosphate uridyltransferase (GALT), or galactose-4’-
epimerase―can lead to galactosemia, GALT deficiency is the most common [2].
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GALT deficiency patients usually show no signs of galactosemia at birth, but after ingestion 
of lactose, most present in the neonatal period with a life-threatening illness characterized by 
food intolerance, vomiting, diarrhea, jaundice, enlarged liver and spleen, lethargy, and 
muscle hypotonia. Early treatment by removal of all galactose from the diet is lifesaving [2, 
3].
In the US, dried-blood-spot (DBS) samples obtained from heel pricks are collected from 
more than 98% of all newborns [4] and used in screening tests for treatable inborn disorders. 
GALT deficiency is one of the core disorders in the US recommended uniform screening 
panel [5, 6]. All US state newborn screening programs include GALT-deficiency tests in 
their newborn screening panels [7], and all US state, regional, and state-associated contract 
newborn screening laboratories participate voluntarily in the GALT component of the 
Newborn Screening Quality Assurance Program (NSQAP) of the Centers for Disease 
Control and Prevention (CDC). In addition to domestic laboratories, newborn screening 
laboratories in more than 70 foreign countries participate in NSQAP [8].
NSQAP routinely conducts research for development of unique DBS quality control (QC) 
materials that assist laboratories with monitoring performance of their newborn screening 
tests. NSQAP collaborated with the Genetic Disease Laboratory Branch of the California 
Department of Public Health to develop DBS QC materials for monitoring the performance 
of GALT screening tests and to classify these materials as GALT-normal or GALT-
deficient.
NSQAP QC materials must be suitable for all screening tests that newborn screening 
laboratories use. All US screening laboratories use one of five GALT assays: in-house 
Beutler-Baluda based qualitative GALT tests [9]; one of two GALT kits from PerkinElmer 
Life and Analytical Sciences—the Neonatal GALT kit or the GSP Neonatal GALT kit—or 
one of two Astoria-Pacific International SPOTCHECK GALT kits—the Uridyltransferase 
50 hour Reagent Kit or the Neonatal GALT Microplate Reagent Kit. NSQAP used 
PerkinElmer kits to evaluate the performance of NSQAP DBS materials by those methods 
and collaborated with Astoria-Pacific to evaluate the performance of NSQAP candidate 
GALT QC materials using the SPOTCHECK kits. The candidate QC materials were also 
evaluated by 26 newborn screening laboratories selected to include all five GALT test 
methods used in the US. The materials were not evaluated by test methods that are used by 
NSQAP participants in other countries but are not available in the US.
In this report, procedures for production of GALT-normal, GALT-intermediate, and GALT-
deficient DBS QC materials are described. GALT activities in DBS materials stored at 
predetermined temperatures and humidities for preselected intervals are compared to 
illustrate the effects of exposure to heat, humidity, and temperature-fluctuations on the 
stability of GALT activity in DBSs. Analytic results are presented to show that the 
NSQAP’s DBS candidate QC materials give comparable performance in all newborn 
screening GALT tests that US laboratories use. This information is intended to guide 
laboratories in the storage and use of DBS materials for routine QC of their GALT screening 
tests.
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2. MATERIALS AND METHODS
2.1. Preparation of paired GALT-normal and GALT-deficient whole blood portions
Freshly collected ABO-compatible units of packed red blood cells and serum were 
purchased from a blood bank (Tennessee Blood Services). The red cell units were combined 
and washed three times with 0.9% sterile saline solution (www.fishersci.com) before 
adjustment to a hematocrit of ≥95% by aspiration of the final saline wash. The serum units 
were combined and clarified by serial filtration through disposable sterilization units of pore 
sizes 0.45 and 0.22 µm (Nalgene), diluted 1:1 with 0.9% saline solution, and used to 
reconstitute the packed red cells to a hematocrit of 50±1%. After thorough mixing, half of 
the blood batch was transferred to overnight storage at 4°C.
The remaining half of the batch was transferred to a volumetric flask, submerged in a 53.5°C 
water bath, and continuously mixed with a mechanical stirring arm for two hours to 
inactivate its GALT content. The flask of heat-treated blood was placed in an ice-water bath 
and stirred to reduce the blood temperature to less than 20°C before transfer to overnight 
storage at 4°C.
This procedure was carried out twice to prepare two independent batches of paired GALT-
normal and GALT-deficient blood portions. The first batch was used to create two sets of 
DBS dose-response materials for internal and external evaluations of candidate blood 
matrixes for DBS QC materials. The second batch was used to prepare a 3-member set of 
DBS GALT QC materials.
2.2. Preparation of DBS dose-response materials
Two sets of dose-response materials were made by combining pre-determined amounts of 
paired GALT-normal and GALT-deficient (heat-treated) blood portions and then dispensing 
these blood mixtures as 100 µL spots onto sheets of horizontally suspended Grade 903 (GE 
Healthcare Biosciences) filter paper. Before preparation of each set of dose-response 
materials, the GALT-normal and GALT-deficient blood portions were brought to room 
temperature (20°–25°C) and filtered through gauze to remove any clots that might have 
formed during storage. All blood portions were gently stirred before and during dispensing 
from handheld automated pipettes. The blood spots were dried overnight under ambient 
conditions before the sheets of DBSs were separated by sheets of weighing paper 
(www.fishersci.com) and placed in Bitran Series S liquid-tight zip-closure specimen bags 
(www.fishersci.com) with desiccant packets (polylam.com) and 30–50% humidity indicator 
cards (www.desiccare.com) to ensure that storage humidity was maintained below 30%. The 
sealed bags of DBS materials were stored at −20°C to await analysis and characterization.
The initial set of DBS dose-response materials (Set A) was made by combining aliquots of 
GALT-normal and GALT-deficient blood to produce intact-cell blood portions containing 
100%, 50%, 40%, 30% and 0% GALT-normal blood and using these portions to produce the 
DBS materials. Immediately after production of Set A dose-response materials, the residual 
100% GALT-normal and 100% GALT-deficient blood portions were stored for two weeks 
at −20°C to hemolyze the erythrocytes. After hemolysis, aliquots of the GALT-normal and 
GALT-deficient blood were combined to produce lysed-cell blood portions containing 
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100%, 50%, 40%, 30%, 20%, 10% and 0% GALT-normal blood. These portions were used 
to produce Set B dose-response materials.
2.3. Production of DBS GALT QC materials
The second batch of paired whole blood portions was brought to room temperature, filtered 
through gauze and used to create a 3-member set of blood spot QC materials consisting of a 
GALT-normal member, a GALT-deficient member, and an intermediate member made from 
a 30:70 combination of the GALT-normal and GALT-deficient blood. The blood portions 
were stirred gently before and while a multi-channel liquid handling system dispensed them 
in 100 µL aliquots onto horizontally suspended sheets of Grade 903 filter paper. The sheets 
of blood spots were dried overnight under ambient conditions before being separated with 
weighing paper, packaged in zip-closure bags with desiccant and humidity indicator cards, 
and stored at −20°C.
2.4. Measurements of GALT activity in DBS materials
NSQAP used Neonatal GALT Kit (PerkinElmer Life and Analytical Sciences) to measure 
GALT activity of all DBS materials. The Genetic Disease Laboratory Branch of the 
California Department of Public Health used Astoria-Pacific Uridyltransferase 50 hour 
Reagent Kits to validate GALT activities of the 3-member set of DBS QC materials. 
Astoria-Pacific International used both SPOTCHECK kit tests—the Uridyltransferase 50 
hour Reagent Kit and the Neonatal GALT Microplate Reagent Kit—to evaluate the 
suitability of the DBS dose-response materials and the 3-member set of DBS QC materials 
for use in those tests. For simplicity, only NSQAP’s analytic results are reported here.
2.5 Characterization of GALT levels and validation of homogeneity of the DBS materials
Duplicate analyses of the first, middle and last sheets of each level of the two sets of DBS 
dose-response materials (intact and lysed red cells) were performed on each of 5 days. The 
acquired data were used in previously described statistical procedures [10] for estimating 
initial marker level in small DBS production batches.
Characterization data from analyses of the 3-member set of DBS GALT QC lots were 
subjected to the statistical protocols NSQAP routinely uses for determining the homogeneity 
of marker distribution and initial marker level in large DBS production batches. To assess 
the homogeneity of every 621-sheet DBS QC production lot, 12 DBS punches were taken 
from each of six sheets (sheets 1, 10, 100, 300, 500 and 621) and analyzed in a single run. 
Evaluations of each homogeneity data set were based on the ratio of among- and within-
sheet variability from a one-way random effects analysis of variance. Homogeneity was 
deemed sufficient as long as the upper limit of the confidence interval for the ratio was less 
than 3 [11]. To estimate the average initial GALT activities of the three lots of DBS QC 
materials, two DBS disks from each lot were analyzed in each of 20 runs. The cumulative 
results were subjected to multi-rule Shewhart control analysis according to NSQAP’s 
institutional guidelines for duplicate analyses of three different QC lots per run [12].
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2.6 Degradation studies design
Accelerated degradation studies of GALT activity were performed to measure separately the 
contributions of storage temperature and humidity to changes in levels of GALT activity in 
DBS samples. Members of each degradation study sample set were stored for pre-
determined intervals under prescribed test conditions before removal to optimal storage 
(−70°C and <30% humidity) to await analysis. The Day 0 member of each DBS sample set, 
in a zip-closure bag with relative humidity maintained below 30%, remained at −70°C 
storage throughout the study to serve as a storage stability control for its sample set.
Paired sets of identical DBSs, taken from the 100% GALT-normal member of the intact-cell 
dose-response materials, were stored at each of four preselected temperatures—45°C, 37°C, 
room temperature, and 4°C—in Bitran Series S storage bags containing cards that indicated 
by color-change humidities below 30% (blue) or above 50% (pink). One DBS of each pair 
was stored with humidity controlled to below 30% by enclosing desiccant packets with the 
DBSs and zip-sealing the bags before storage. The other DBS of each pair was stored 
without desiccant in an open Bitran bag in a high-humidity chamber which was monitored 
by periodic hygrometer readings to maintain relative humidity above 90%. Additionally, a 
single sample set was stored at −20°C and low humidity. At predetermined intervals 
throughout the degradation studies, DBSs from all sample sets were transferred to optimal 
storage at −70°C. Immediately before this transfer, desiccant packets were added to the bags 
containing DBSs that had been stored at high humidity, and those bags were zip-sealed to 
ensure that the DBSs were stored at optimal humidity. The GALT activity levels of all 
samples in each complete sample set were measured in triplicate in a single analytical run.
Geometric means of triplicate measurements of initial (Day 0) GALT activity and GALT 
activity remaining on the last day of each degradation study were used to determine the 
percentage of the initial GALT activity level that was lost during the study. GALT losses 
from DBSs stored at low humidity were attributed to the effects of the elevated storage 
temperature. The percentage loss of activity from each sample set stored at low humidity 
was subtracted from the percentage loss of activity sustained by its paired sample set stored 
at high humidity, and the difference was attributed to the effects of elevated storage 
humidity.
2.7 Stability of GALT activity during the “active life” of DBS QC materials
Typically, supplies of NSQAP DBS QC materials for routinely monitoring the performance 
of laboratory tests are stored at 4°C and brought to room temperature each time DBS disks 
are punched for analysis. Reserve supplies of the DBS QC materials are stored at −20°C and 
brought to room temperature at infrequent intervals to replenish the supplies of QC materials 
for routine use. To estimate the effect of temperature fluctuations on GALT activity, DBS 
materials were stored at 4°C or −20°C and subjected to repeated brief excursions to room 
temperature. The sheets of DBS materials for each of these studies were from a single 
GALT-normal DBS production batch and were stored in zip-closure bags with humidity 
controlled to below 30%. At pre-determined intervals throughout month-long studies, the 
sets of stored DBS materials were transferred to room temperature for 30 to 60 minutes 
before the storage bags were opened and DBSs from each storage study sample set were 
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harvested. After each DBS harvest, the remaining portions of the DBS sheets were replaced 
in their zip-closure storage bags and returned immediately to their respective storage study 
temperatures. The harvested DBSs from each sample set were protected with weighing 
paper and packaged in zip-closure bags containing desiccant packets and a humidity 
indicator card. These bags were zip-sealed and immediately transferred to storage at −70°C 
to await analysis. The GALT activity levels of all samples in each complete sample set were 
measured in triplicate in a single analytical run. Geometric means of triplicate GALT 
activity measurements were used to assess the effects of temperature fluctuations on GALT 
activity in DBS QC materials.
2.8. External evaluation of NSQAP’s DBS dose-response materials by all GALT methods 
that US newborn screening laboratories use
Identical 15-member panels of DBS materials were prepared from the two sets of DBS 
GALT dose-response materials and DBS samples from a GALT-normal blood donor, a 
GALT-deficient blood donor, and a previously distributed proficiency testing specimen from 
NSQAP’s DBS library. These panels were analyzed by laboratories that used the Astoria-
Pacific 50 Hour Reagent Kit (6 laboratories), Astoria-Pacific Neonatal Microplate Reagent 
Kit (4 laboratories), Beutler-type non-kit methods (5 laboratories), PerkinElmer Neonatal 
Kit (5 laboratories), and PerkinElmer GSP Neonatal Kit (6 laboratories). All laboratories 
reported clinical classifications of the samples.
3. RESULTS
3.1. Characterization of dose-response materials
GALT activities in both sets of DBS dose-response materials were proportional to the 
percentage of GALT-normal blood contained in the whole blood matrixes of the pools 
(Table 1). Average initial GALT activities of all dose-response pools that contained at least 
30% GALT-normal blood were above the 3.0 enzyme activity units/gram hemoglobin (U/g 
Hb) cutoff value used by NSQAP to classify specimens as presumptive positive or negative 
for GALT deficiency. The average GALT activities of dose-response materials made from 
blood that had been frozen to hemolyze the red cells were about 10% lower than the average 
activities of the corresponding materials made from freshly prepared blood with intact red 
cells.
3.2 Characterization of initial GALT levels and validation of homogeneity of GALT 
distribution in the 3-member set of DBS QC materials
The distribution of GALT activity in each of the three lots that comprised the set of DBS QC 
materials was found to be homogenous. (Among-card variance of every lot was less than its 
within-card variance.) The average GALT activities of the three QC lots and the standard 
deviations and 95% confidence limits around those averages were: GALT-normal lot—8.2 ± 
0.9 U/g Hb (6.4–10.0 U/g Hb); GALT-intermediate lot—3.5 ± 0.3 U/g Hb (2.9–4.1 U/g Hb); 
and GALT-deficient lot—1.5 ± 0.1 U/g Hb (1.3–1.7 U/g Hb).
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3.3 Stabilities of GALT in blood spots stored at low and high humidities for predetermined 
intervals at preselected temperatures
The losses of GALT activity after each storage interval at five temperatures (45°C, 37°C, 
room temperature, 4°C, and −20°C) are shown in Figure 1 as the remaining percentages of 
their respective initial (Day 0) activities. All paired DBS samples stored at low relative 
humidity retained more of their initial GALT activity than did their paired samples stored at 
high humidity. Losses of GALT activity that occurred during low humidity storage (and 
were attributed to effects of the storage temperatures) were subtracted from the losses that 
occurred during high humidity storage to find the percentage of losses attributable to the 
effects of high storage humidity. Losses attributable to high relative humidity ranged from 
14% loss from DBSs stored at 45°C to 40% loss from samples stored at 4°C (Table 2).
3.4 Stability of GALT activity during the “active life” of DBS QC materials
Each point in Figure 2 represents the geometric mean of triplicate measurements of GALT 
activity in DBS QC materials that were stored at 4°C and subjected to 0–23 excursions to 
room temperature (Figure 2A) or were stored at −20°C and subjected to 0–14 excursions to 
room temperature (Figure 2B). During a month-long study, DBSs stored at 4°C showed a 
decline in GALT activity after the 19th excursion to room temperature. DBSs stored at 
−20°C showed no decline in GALT activity after the 14 excursions to room temperature that 
comprised the freeze/thaw study.
3.5. External evaluation of candidate GALT QC materials
All 26 participants in the external evaluation reported qualitative (clinical) assessments of 
“within normal limits” or “outside normal limits” for each of the 15 samples in the 
evaluation test panel (Table 3). Twenty-five of 26 participants classified the presumptive 
GALT-deficient sample in the Set A dose-response materials (made from intact-cell blood) 
as “outside normal limits”; all participants classified the presumptive GALT-deficient 
sample in dose-response materials Set B (made from hemolyzed blood) as “outside normal 
limits”. All participants classified the presumptive GALT-normal samples (made from 100% 
GALT-normal blood) in both sets of dose-response materials as “within normal limits”.
4. DISCUSSION
NSQAP routinely conducts research for development of unique DBS QC materials that 
assist laboratories with monitoring the performance of their newborn screening tests. 
Development of QC materials for DBS GALT tests was challenging because: 1) GALT is 
associated with red blood cells and GALT-deficient red cells are not available 
commercially; 2) DBS samples must be stored under carefully controlled conditions to avoid 
loss of GALT activity [13]; 3) the DBS QC materials must be suitable for use in all GALT 
tests that newborn screening laboratories use; and 4) GALT reporting units for quantitative 
data are not standardized among all GALT test methods.
The Genetic Disease Laboratory Branch of the California Department of Public Health 
implemented the innovative use of a 1:1 serum:saline solution to reconstitute packed red 
cells to 50% hematocrit before heat-treatment to reduce GALT activity. This innovation 
Adam et al. Page 7













reduced non-specific background fluorescence of the blood matrix thus enabling production 
of DBS QC materials that were suitable for monitoring the performance of their GALT tests. 
NSQAP followed California’s protocol for preparation of the blood matrix but used a more 
rigorous heat-treatment to produce GALT-deficient DBS QC materials with lower GALT 
activities than were desired by the California laboratory.
Historically, NSQAP QC materials for newborn screening tests have been made from blood 
with hemolyzed red cells. For historical reference, the lysed-cell blood matrix for GALT QC 
materials was evaluated. The lower GALT activities found in DBS materials made from the 
lysed-cell blood are consistent with the finding that the serum absorption volumes of disks 
punched from DBSs made from lysed cell blood are lower than those of identical punches 
taken from DBSs made from intact-cell blood [16]. Although both the intact-cell and the 
lysed-cell blood matrixes produced potentially acceptable GALT-normal and GALT-
deficient candidate DBS QC materials, the higher GALT activity of the intact-cell blood 
matrix made it the more attractive choice for use in the DBS GALT QC materials.
In addition to GALT-normal and GALT-deficient QC materials, the NSQAP set of materials 
also contained an intermediate control for monitoring the performance of DBS tests near the 
GALT activity cutoff level used to classify test results as presumptive positive or negative 
for GALT deficiency. The mean GALT activities, standard deviations and confidence limits 
that were derived from the NSQAP characterizations of the three DBS GALT QC materials 
are for reference only. Each laboratory participating in the NSQAP must use its GALT test 
method to establish its own mean values and confidence limits for the QC materials [17].
Understanding the susceptibilities in DBS samples to temperature related and moisture 
related degradation is important for maintaining sample integrity for high quality 
measurements. Accelerated degradation studies were used to measure the contributions of 
temperature and humidity to the degradation of GALT activity in stored DBS materials. 
Declines in enzyme activity increased as storage temperature increased from 4°C to 45°C. 
Although exposure to elevated humidity accelerated losses of GALT activity during studies 
carried out at 45°C, 37°C and room temperature, most of these enzyme activity losses were 
attributable to the effects of exposure to the storage temperatures. In contrast, most of the 
loss of GALT activity in DBS stored at 4°C was attributable to the effects of exposure to 
elevated humidity. GALT stability in DBSs stored at −20°C was only studied at low 
humidity because of difficulty in controlling humidity in the frozen state. The findings that 
GALT lost substantial activity during storage at elevated temperatures and low or high 
humidity are consistent with a previously reported controlled study of GALT stability [13] 
and with the observation that population means of GALT activities in newborn screening 
samples were more than 20% lower in summer than in winter [18].
GALT activity in QC materials used to monitor assay performance must be stable. The 
GALT activity in NSQAP DBS QC materials stored at 4°C declined after 19 excursions 
from 4°C to room temperature. This finding suggests that NSQAP GALT QC materials 
stored at 4°C for routine use in laboratories with 5-day work-weeks should be replaced at 3-
week intervals to maintain sample integrity.
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Clinical classifications reported by participants in the external evaluations of dose-response 
materials made from 100% GALT-normal blood were concordant. One evaluator that used a 
qualitative method classified a 100% GALT-deficient intact-cell DBS material as “within 
normal limits”; all others classified it as “outside normal limits”. The members of the sets of 
dose-response materials for which clinical assessments were most evenly divided between 
positive and negative classifications were presumed to be the members with GALT activity 
closest to newborn screening programs’ cutoff values—i.e., they were presumed to be 
candidate intermediate controls. In dose-response materials made from blood with intact red 
cells, the presumptive-borderline intermediate control contained 30% GALT-normal blood. 
Because the GALT DBS QC materials were also made from blood with intact red cells, 30% 
GALT-normal blood was used to prepare an intermediate DBS QC material that was 
targeted to the cutoff value.
Building a reliable QC system for monitoring the performance of newborn screening tests is 
critical for understanding and controlling the variables that may influence the outcomes of 
these tests. Implementation of a robust analytic QC system contributes to confidence in the 
newborn screening test results. The special studies reported here provide essential QC 
production and storage guidelines to scientists contemplating production of in-house DBS 
QC materials for use with non-kit GALT tests or for adding intermediate controls to 
supplement GALT-normal and GALT-deficient DBS QC materials provided by GALT kit 
producers. The NSQAP QC materials for DBS GALT tests can strengthen existing QC 
systems by providing a secondary level of control to transcend production lots of primary 
QC materials and monitor long-term assay performance.
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Recoveries of galactose-1-phosphate uridyltransferase (GALT) from dried blood spots 
stored at controlled temperatures for predetermined intervals in low-humidity and high-
humidity environments. Samples stored at −20°C were stored at low humidity only.
● = low humidity ○ = high humidity
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Galactose-1-phosphate uridyltransferase (GALT) activities recovered from dried blood spots 
stored with relative humidity controlled to less than 30% and subjected to repeated 
excursions to room temperature from (A) 4°C or (B) −20°C
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Table 2
PercentagesA of galactose-1-phosphate uridyltransferase (GALT) activity lost from dried blood spots stored in 














(°C) (days) (%) (%) (%)C
45 14 68 54 14
37 35 79 53 26
RTD 91 72 52 20
4 182 63 23 40
A
Percentages shown were derived from geometric means of triplicate determinations.
B
Low relative humidity <30%; high relative humidity >50%.
C
Derived by subtracting loss during storage at low humidity from loss during storage at high humidity
D
RT=room temperature
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TABLE 3








1 Dose-response Set AA 100% 0% 26 0
2 Dose-response Set A 50% 50% 22 4
3 Dose-response Set A 40% 60% 17 9
4 Dose-response Set A 30% 70% 14 12
5 Dose-response Set A 0% 100% 1 25
6 Positive control B NA NA 1 25
7 Dose-response Set BC 100% 0% 26 0
8 Dose-response Set B 50% 50% 17 9
9 Dose-response Set B 40% 60% 14 12
10 Dose-response Set B 30% 70% 8 18
11 Dose-response Set B 20% 80% 4 22
12 Dose-response Set B 10% 90% 1 25
13 Dose-response Set B 0% 100% 0 26
14 Blind QC sampleD NA NA 26 0
15 Negative controlE NA NA 26 0
A




Made from blood with hemolyzed red cells
D
An archived GALT-normal proficiency testing specimen
E
A GALT-normal patient sample
F
WNL = within normal limits
G
ONL = outside normal limits
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